株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌治療薬の世界市場:再発・転移部位の重視

Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions

発行 BCC Research 商品コード 762926
出版日 ページ情報 英文 288 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.62円で換算しております。
Back to Top
癌治療薬の世界市場:再発・転移部位の重視 Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions
出版日: 2018年12月21日 ページ情報: 英文 288 Pages
概要

世界における癌治療薬の市場規模は、2018年の1,281億米ドルから、2023年までに1,820億米ドルへ拡大すると予測され、2018年から2023年にかけては7.3%のCAGR (年間複合成長率) が見込まれています。

当レポートでは、世界の癌治療薬市場について調査し、世界市場の概要、国別のデータと分析、転移・再発を含めた癌の発展段階の説明、現在の診断法に関する考察、薬理学的アプローチ、経済的負担に関する情報、および主要企業のプロファイルなどを提供しています。

第1章 イントロダクション

第2章 サマリー

第3章 癌のバイオロジー

  • 概要
  • 癌の病因
  • 癌の病期
  • 癌の転移

第4章 疾患および癌の経済的負担

  • 癌の負担
  • 癌:発症率・有病率の統計分析
  • 癌の地域的なパターン

第5章 癌の転移・再発に対する治療アプローチ

  • 癌の転移・再発に対する治療アプローチ
  • 非製薬的アプローチ
  • 薬物療法
  • 標的型生物学的療法
  • 遺伝子療法
  • 癌血管の増殖を抑制する医薬品 (血管新生抑制)
  • オーダーメイド癌治療 (精密医療)
  • 主な癌転移の治療選択肢

第6章 癌の治療薬:上市済み製品・パイプライン分析

  • 概要
  • 主な上市薬のプロファイル
  • 治験
  • 肺癌
  • 乳癌
  • 前立腺癌
  • 膀胱癌
  • 胃癌
  • その他 (肝臓癌、リンパ腫、白血病、卵巣癌、膵臓癌)

第7章 規制・医療費償還の状況

  • 米国
  • カナダ
  • 欧州
  • 日本
  • 中国
  • インド
  • 韓国
  • ブラジル
  • アルゼンチン
  • メキシコ
  • 南アフリカ
  • サウジアラビア

第8章 癌治療薬:世界・地域市場の分析

  • 概要
  • 世界の癌治療薬市場
  • 北米
  • 欧州
  • アジア太平洋
  • 中米・ラテンアメリカ
  • 中東・アフリカ

第9章 特許レビュー/新規開発

第10章 競合情勢

第11章 企業プロファイル

付録:頭字語

BBC Researchについて

図表

List of Tables

  • Summary Table: Global Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 1: Cancer Incidence in the U.S., by Sex, 2017
    • Table 2: Number of Deaths from Cancer in the U.S., by Sex, 2017
    • Table 3: Cancer Treatment Options
    • Table 4: Cancer Drug Treatment Classes
    • Table 5: FDA-Approved Intravenous Therapeutic Monoclonal Antibodies Used to Treat Cancer, 1997-2017
    • Table 6: Approved Tyrosine Kinase Inhibitors (TKIs) Used to Treat Cancer
    • Table 7: Common Chemotherapeutic Agents for Recurrent and Metastatic Breast Cancer
    • Table 8: Drugs Approved for the Treatment of Lung Cancer
    • Table 9: Treatment Options for Stage IV and Recurrent Colon Cancer
    • Table 10: Hormone Therapy for Prostate Cancer
    • Table 11: Drugs Approved for Prostate Cancer
    • Table 12: Drugs Approved for Stomach (Gastric) Cancer
    • Table 13: Drugs Combinations Approved for Stomach (Gastric) Cancer
    • Table 14: Drugs Approved for Gastroenteropancreatic Neuroendocrine Tumors
    • Table 15: Drugs Approved for the Treatment of Melanoma
    • Table 16: Drugs Approved for Pancreatic Cancer
    • Table 17: Drugs Approved for Pancreatic Cancer
    • Table 18: Treatment Option Overview for Thyroid Cancer
    • Table 19: Drugs Approved for Thyroid Cancer
    • Table 20: Treatment Option Overview for Endometrial Cancer
    • Table 21: Profiles of Top Marketed Drugs
    • Table 22: Lung Cancer Phase III Clinical Trials, 2018*
    • Table 23: Lung Cancer Phase II Clinical Trials, 2018*
    • Table 24: Lung Cancer Phase I Clinical Trials, 2018*
    • Table 25: Breast Cancer Phase III Clinical Trials, 2018*
    • Table 26: Breast Cancer Phase II Clinical Trials, 2018*
    • Table 27: Breast Cancer Phase I Clinical Trials, 2018*
    • Table 28: Colorectal Cancer Phase III Clinical Trials, 2018*
    • Table 29: Colorectal Cancer Phase II Clinical Trials, 2018*
    • Table 30: Colorectal Cancer Phase I Clinical Trials, 2018*
    • Table 31: Bladder Cancer Phase III Clinical Trials, 2018*
    • Table 32: Bladder Cancer Phase II Clinical Trials, 2018*
    • Table 33: Bladder Cancer Phase I Clinical Trials, 2018*
    • Table 34: Gastric Cancer Phase III Clinical Trials, 2018*
    • Table 35: Gastric Cancer Phase II Clinical Trials, 2018*
    • Table 36: Gastric Cancer Phase I Clinical Trials, 2018*
    • Table 37: Others Phase III Clinical Trials, 2018*
    • Table 38: Others Phase II Clinical Trials, 2018*
    • Table 39: Others Phase I Clinical Trials, 2018*
    • Table 40: Global Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 41: North American Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 42: North American Cancer Therapeutics Market, by Country, Through 2023
    • Table 43: European Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 44: European Cancer Therapeutics Market, by Country, Through 2023
    • Table 45: Asia-Pacific Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 46: Asia-Pacific Cancer Therapeutics Market, by Country, Through 2023
    • Table 47: Central and Latin American Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 48: Central and Latin American Cancer Therapeutics Market, by Country, Through 2023
    • Table 49: Middle East and Africa Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 50: Patent Applications Filed on Metastatic Breast Cancer Therapeutics, 2016 - October 2017
    • Table 51: Patent Applications Filed on Metastatic Prostate Cancer Therapeutics, November 2015 - January 2018
    • Table 52: Patent Applications Filed on Metastatic Lung Cancer Therapeutics, August 2015 - January 2018
    • Table 53: Latest Patent Publications Cited Relating to Other Metastatic Cancers, December 2015 - July 2018
    • Table 54: Pfizer Inc.: Patent Expiry Dates for Leading Cancer Drugs
    • Table 55: Merck & Co.: Patent Status of Leading Oncology Products
    • Table 56: Johnson & Johnson: Patent Status of Leading Oncology Products
    • Table 57: F Hoffman-La Roche: Patent Status of Leading Oncology Products
    • Table 58: Sanofi SA: Patent Status of Leading Oncology Products
    • Table 59: AstraZeneca plc: Patent Status of Leading Oncology Products
    • Table 60: Celgene: Patent Status of Leading Oncology Products
    • Table 61: Eli Lilly: Patent Status of Leading Oncology Products
    • Table 62: Recent Industry Developments, December 2017 Through September 2018
    • Table 63: AbbVie, Inc.: Company Financials, by Product, 2015-2017
    • Table 64: Amgen: Company Financials, 2015-2017
    • Table 65: Array Biopharma Inc.: Clinical Stage Drug Portfolio
    • Table 66: AstraZeneca plc.: Company Net Revenue, 2015-2017
    • Table 67: AstraZeneca plc: Company Financials, by Therapeutic Product Group, 2015-2017
    • Table 68: AstraZeneca plc: Company Financials, by Oncology Product Group, 2015-2017
    • Table 69: Bristol-Myers Squibb: Revenue, 2015-2017
    • Table 70: Bristol-Myers Squibb: Oncology Product Sales, 2015-2017
    • Table 71: Celgene Corp.: Company Financials, by Product, 2015-2017
    • Table 72: GlaxoSmithKline: Oncology Product Pipeline
    • Table 73: Gilead Sciences, Inc.: Product Pipeline
    • Table 74: Eli Lilly and Co.: Net Revenue, by Segment, 2015-2017
    • Table 75: Eli Lilly and Co.: Oncology Product Sales, 2015-2017
    • Table 76: F Hoffmann-La Roche Ltd.: Net Revenue, by Segment, 2015-2017
    • Table 77: F Hoffman-La Roche Ltd.: Pharmaceutical Division Oncology Product Sales, 2015-2017
    • Table 78: Johnson & Johnson: Company Financials, by Segment, 2015-2017
    • Table 79: Johnson & Johnson: Pharmaceutical Therapeutic Area Product Sales, 2015-2017
    • Table 80: Johnson & Johnson: Oncology Product Sales, 2015-2017
    • Table 81: Merck & Co., Inc.: Therapeutic Area Product Sales, 2015-2017
    • Table 82: Merck & Co., Inc.: Oncology Product Sales, 2015-2017
    • Table 83: Novartis AG: Company Financials, by Business Segment, 2015-2017
    • Table 84: Novartis AG: Major Development Projects
    • Table 85: Pfizer Inc.: Company Financials, 2015-2017
    • Table 86: Pfizer Inc.: Innovative Health (IH) Division Financials, 2015-2017
    • Table 87: Pfizer Inc.: Innovative Health (IH) Division Oncology Product Sales, 2015-2017
    • Table 88: Sanofi SA: Company Financials, 2015-2017
    • Table 89: Sanofi SA: Oncology Product Sales, 2015-2017
    • Table 90: Commonly Used Acronyms Associated with Metastatic and Recurrent Cancer

List of Figures

  • Summary Figure: Global Cancer Therapeutics Market Share, by Cancer Type, 2017
    • Figure 1: Top Selling Oncology Drugs, 2017
    • Figure 2: Distribution of Clinical Trials for Cancer Metastases and Recurrence, by Cancer Type, 2018*
    • Figure 3: Global Cancer Therapeutics Market, 2017-2023
    • Figure 4: Global Cancer Therapeutics Market Share, by Cancer Type, 2017
    • Figure 5: North American Cancer Therapeutics Market, by Cancer Type, 2017-2023
    • Figure 6: European Cancer Therapeutics Market, by Cancer Type, 2017-2023
    • Figure 7: Asia-Pacific Cancer Therapeutics Market, by Cancer Type, 2017-2023
    • Figure 8: Central and Latin American Cancer Therapeutics Market, by Cancer Type, 2017-2023
    • Figure 9: Middle East and African Cancer Therapeutics Market, by Cancer Type, 2017-2023
    • Figure 10: Global Cancer Therapeutics Market Share, by Company, 2017
目次
Product Code: PHM177B

Report Highlights:

The global cancer therapeutics market should grow from $128.1 billion in 2018 to $182.0 billion by 2023 at a compound annual growth rate (CAGR) of 7.3% for the period of 2018-2023.

All other cancers therapeutics market should grow from $39.4 billion in 2018 to reach $55.5 billion by 2023 at a CAGR of 7.1% for the period of 2018-2023.

Lung cancer therapeutics market should grow from $16.7 billion in 2018 to reach $24.6 billion by 2023 at a CAGR of 8.0% for the period of 2018-2023.

Report Scope:

The report on "Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions" presents qualitative and quantitative information on the current market dynamics that are influencing the market. It covers a background to cancer, types of cancer, pathogenesis of cancer, and stages of cancer development, including the mechanisms of metastasis and recurrences. It also includes the disease burden through understanding the epidemiology of various cancers. Treatment patterns, which include the pharmacological approaches (covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy, and combinatorial therapy) and non-pharmacological approaches (including surgeries and radiation) are covered to present the various therapeutic options available for the patients. Also included in the report are analyses of key marketed products; the current clinical trial landscape; patent landscape and recent product approvals; regulatory landscape; and reimbursement landscape across different demographics. An overview of the demographics of key regions, namely, North America, Europe, Asia-Pacific, Latin America and the Middle East, with potential growth is also covered. Strategies of global companies engaged in the cancer therapeutic space and the profiles of top companies are also covered.

The quantitative information covered in the report includes -

  • Estimates of the market size of the cancer therapeutics used for treating metastases and recurrence states of cancer. The key cancer types covered include lung cancer, breast cancer, liver cancer, stomach cancer, prostate cancer, colorectal cancer, gastric cancer, cervical cancer, bladder cancer, kidney cancer, ovarian cancer and others. Others includes leukemia, lymphoma, multiple myeloma, brain tumor, thyroid cancer and uteral cancer.
  • Further growth potential and forecast information has been covered for the overall cancer therapeutics market and for segments-cancer types, by region and by country.

Market values provided are based on total revenues of cancer therapeutics drug manufacturers.

As a cancer therapeutics (emphasis on recurrent and metastatic cancer) market report, only pharmacological therapy is covered for computation of the market size. Interventions involving surgeries, radiation, ablations and other medical device interventions are excluded from the market size computation and only qualitative information on the same is covered.

Report Includes:

  • 36 data tables and 55 additional tables
  • An overview of global cancer therapeutics market with special focus on recurrent and metastatic divisions
  • Country specific data and analysis for US, Canada, Mexico, Germany, Italy, U.K, France, China, India, Japan, South Korea, Brazil, Argentina and Chile
  • Description of stages of cancer development including the mechanisms of metastasis and recurrences
  • Insights of current diagnostics such as medical imaging, in vitro diagnostics technologies and treatment patterns
  • Snapshot of pharmacological approaches covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy and combinatorial therapy and non-pharmacological treatments such as surgeries, radiation
  • Complete understanding of causes, risk factors, prevalence and incidence of cancer
  • Information on economic cost burden due to cancer
  • Dossier of recent industry events, product innovation, acquisition, partnership and collaborations and competitor strategies
  • Comprehensive company profiles of major market players of the industry including AbbVie, Inc., Biogen Inc., GlaxoSmithKline plc (GSK), Eli Lilly and Co., Merck & Co., Inc., and Pfizer Inc.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Scope of Report
  • Information Sources
  • Methodology
    • Market Estimation and Forecast
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary

  • Key Findings

Chapter 3: Biology of Cancer

  • Overview
    • Lung Cancer
    • Breast Cancer
    • Melanoma
    • Colorectal Cancer
    • Prostate Cancer
    • Cervical Cancer
  • Pathogenesis of Cancer
    • Genetic Changes
  • Stages of Cancer
    • The TNM Staging System
    • Number Staging Systems
  • Cancer Metastases
    • Routes of Metastasis
    • Drug Resistance
    • Inherent Resistance
    • Acquired Resistance

Chapter 4: Disease and Economic Burden of Cancer

  • Cancer Burden
    • Tobacco Use and Statistics
    • Alcohol Abuse and Cancer Statistics
    • Infectious Diseases and Cancer
    • Inherited Genes/Diseases and Cancer
    • Sun, Ultraviolet Radiation and Cancer
    • Hormones and Cancer
  • Cancer: A Statistical Analysis of the Disease Incidence and Prevalence
    • Incidence and Prevalence Rates for Major Cancer Types
  • Regional Patterns of Cancer
    • Europe
    • North America
    • Asia-Pacific
    • Latin and Central America
    • Middle East and Africa

Chapter 5: Treatment Approaches to Cancer Metastases and Recurrence

  • Treatment Approaches to Cancer Metastases and Recurrence
  • Non-pharmaceutical Approaches
    • Surgery for Cancer
    • Radiotherapy for Cancer
    • Ablation Therapy
  • Pharmacological Therapies
    • Cytotoxic Cancer Chemotherapy
    • Hormone-based Cancer Drugs
  • Targeted Biologic Therapy
    • Monoclonal Antibodies
    • Immune Checkpoint Inhibitors
    • Cancer Growth Blockers
  • Gene Therapy
  • Drugs That Block Cancer Blood Vessel Growth (Antiangiogenics)
  • Personalized Cancer Therapy (Precision Medicine)
  • Treatment Options for Selected Cancer Metastases
    • Breast
    • Bladder Cancer
    • Lung
    • Colorectal Cancer
    • Standard Treatment Options for Stage IV and Recurrent Colon Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Melanoma
    • Kidney Cancer
    • Transitional Cell Cancer (TCC) of the Renal Pelvis and Ureter
    • Pancreatic Cancer
    • Thyroid Cancer
    • Stage I and Stage II Endometrial Cancer
    • Stage III, Stage IV and Recurrent Endometrial Cancer

Chapter 6: Cancer Therapeutics: Marketed Products and Pipeline Analysis

  • Overview
    • Top Selling Oncology Drugs in 2017
  • Profiles of Selected Marketed Drugs
  • Clinical Trials
  • Lung Cancer
    • Phase III Clinical Trials
    • Phase II Clinical Trials
    • Phase I Clinical Trial
  • Breast Cancer
    • Phase III Clinical Trials
    • Phase II Clinical Trials
    • Phase I Clinical Trials
  • Colorectal Cancer
    • Phase III Clinical Trials
    • Phase II Clinical Trials
    • Phase I Clinical Trials
  • Bladder Cancer
    • Phase III Clinical Trials
    • Phase II Clinical Trials
    • Phase I Clinical Trials
  • Gastric Cancer
    • Phase III Clinical Trials
    • Phase II Clinical Trials
    • Phase I Clinical Trials
  • Others (Kidney Cancer, Lymphoma, Leukemia, Ovarian, Pancreatic)
    • Phase III Clinical Trials
    • Phase II Clinical Trials
    • Phase I Clinical Trials

Chapter 7: Regulations and Reimbursement Landscape

  • The United States
  • Canada
  • Europe
    • Mutual Recognition Procedure (MRP)
    • Decentralized Procedure (DCP)
    • Centralized Procedure (CP)
  • Japan
    • Marketing Authorization System
    • Pharmaceutical Reimbursement Approval Process in Japan
  • China
    • Pharmaceutical Regulatory and Legislative Developments in China
  • India
    • Pharmaceutical Regulatory and Legislative Developments in India
  • South Korea
    • Regulatory and Legislative Requirements
    • Pharmaceutical Regulatory and Legislative Developments in South Korea
    • Pharmaceutical Reimbursement Landscape in South Korea
  • Brazil
    • Market Entry and Reimbursement of Pharmaceuticals
  • Argentina
    • Regulatory and Legislative Requirements
  • Mexico
    • Regulation and Regulation Governing Drugs in Mexico
    • Health Insurance Structure in Mexico
  • South Africa
    • Regulatory Requirementsin South Africa
    • Health Insurance Structure in South Africa
    • Reimbursement of Pharmaceuticals in South Africa
  • Saudi Arabia
    • Pharmaceutical Regulatory Requirements in Saudi Arabia
    • Health Insurance Structure in Saudi Arabia

Chapter 8: Cancer Therapeutics: Analysis of Global and Regional Markets

  • Overview
  • Global Cancer Therapeutics Market
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • North America
    • Market Dynamics in North America
    • United States
    • Canada
  • Europe
    • Market Drivers
    • Market Restraints
    • France
    • Germany
    • U.K.
    • Spain
    • Italy
  • Asia-Pacific
    • Market Drivers
    • Market Restraints
    • Japan
    • China
    • India
  • Central and Latin America
    • Market Drivers
    • Market Restraints
    • Brazil
    • Argentina
  • Middle East and Africa
    • Market Drivers
    • Market Restraints

Chapter 9: Patent Review/New Developments

  • Patent Applications by Clinical Application
    • Patent Applications Filed on Metastatic Breast Cancer Therapeutics
    • Patent Applications Filed on Metastatic Prostate Cancer Therapeutics
    • Patent Applications Filed on Metastatic Lung Cancer Therapeutics
    • Patents Applications Filed on Therapeutics for Other Cancer Types
  • Patents and Expiry Dates for Major Products by Leading Suppliers
    • Pfizer Inc.
    • Merck & Co.
    • Johnson & Johnson
    • F Hoffman-La Roche
    • Sanofi SA
    • Novartis AG
    • AbbVie, Inc.
    • AstraZeneca plc
    • Celgene
    • Eli Lilly
    • Gilead Sciences
  • Patents and Expiry Dates for Other Products and Suppliers
    • Targeting Breakpoint Cluster Region-Abelson (BCR-ABL)
    • Targeting Epidermal Growth Factor Receptor (EGFR/ERBB1)
    • Targeting Vascular Endothelial Growth Factor Receptor (VEGFR), PDGFR and Ret Proto-Oncogene (RET)
    • Impact of Patent Expiries

Chapter 10: Competitive Landscape

  • Overview
  • Leading Companies
    • Roche
    • Novartis
    • Celgene
    • Bristol-Meyers Squibb
    • Johnson & Johnson
  • Recent Developments

Chapter 11: Company Profiles

  • ABBVIE, INC.
    • Company Overview
    • Financial Information
    • Products
    • Clinical Developments
  • AMGEN
    • Company Overview
    • Financial Information
    • Products
  • ARRAY BIOPHARMA INC.
    • Company Overview
    • Products
    • AstraZeneca plc
    • Company Overview
    • Financial Information
    • Key Developments
  • ASTELLAS PHARMA INC.
    • Company Overview
    • Products
  • BAYER HEALTHCARE
    • Company Overview
    • Products
  • BRISTOL-MYERS SQUIBB
    • Company Overview
    • Financial Information
    • Products
  • BIOGEN INC.
    • Company Overview
  • CELGENE CORP.
    • Company Overview
    • Financial Information
    • Products
  • CELLDEX THERAPEUTICS INC.
    • Company Overview
    • Products
  • GLAXOSMITHKLINE
    • Company Overview
  • GILEAD SCIENCES, INC.
    • Company Overview
    • Product
  • ELI LILLY AND CO.
    • Company Overview
    • Financial Information
    • Products
  • EISAI CO. LTD.
    • Company Overview
    • Products
  • F HOFFMAN-LA ROCHE LTD.
    • Company Overview
    • Financial Information
    • Products
    • Key Developments
  • IMMUNOCELLULAR THERAPEUTICS LTD.
    • Company Overview
    • Products
  • IMMUNOGEN INC.
    • Company Overview
  • INCYTE CORP.
    • Company Overview
  • INFINITY PHARMACEUTICALS, INC.
    • Company Overview
  • JOHNSON & JOHNSON
    • Company Overview
    • Financial Information
    • Products
  • MERCK & CO., INC.
    • Financial Information
    • Products
  • NOVARTIS AG
    • Company Overview
    • Financial Information
    • Products
    • Clinical Development
    • Key Developments
  • NEW LINK GENETICS CORP.
    • Company Overview
  • OTSUKA HOLDINGS CO. LTD.
    • Company Overview
  • PFIZER INC.
    • Company Overview
    • Financial Information
    • Key Developments
  • REGENERON PHARMACEUTICALS INC.
    • Company Overview
  • SANOFI SA
    • Company Overview
    • Financial Information
    • Products
    • Key Developments
  • SELLAS LIFE SCIENCES GROUP
    • Company Overview
  • TAKEDA PHARMACEUTICALS
    • Company Overview
  • VERASTEM INC.
    • Company Overview

Chapter 12: Appendix: Acronyms

Back to Top